Skip to main content

IQVIA Holdings Value Stock - Dividend - Research Selection

Iqvia s

ISIN: US46266C1053 , WKN: A2JSPM

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Which S&P500 stocks are gapping on Wednesday?

2026-06-17
Curious about the market action on Wednesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.

Lyft upgraded, Leidos downgraded: Wall Street's top analyst calls

2026-06-17
Lyft upgraded, Leidos downgraded: Wall Street's top analyst calls

Morgan Stanley favors Charles River Over IQVIA in CRO sector reset

2026-06-17
Investing.com -- Morgan Stanley upgraded contract research organization (CRO) provider Charles River Laboratories while downgrading IQVIA, arguing that improving biotech funding and portfolio changes create a more attractive risk-reward profile for Charles River, while longer-term uncertainty tied to artificial intelligence and pharma insourcing weighs on IQVIA.

IQVIA (IQV): Buy, Sell, or Hold Post Q1 Earnings?

2026-06-17
Over the last six months, IQVIA’s shares have sunk to $177.52, producing a disappointing 19.8% loss - a stark contrast to the S&P 500’s 12.4% gain. This might have investors contemplating their next move.

Delta Air Lines To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday

2026-06-17
Top Wall Street analysts changed outlook on top names. Baird raised prices for Ryder System and J B Hunt, Needham for Glaukos, B of A for CSX, Morgan Stanley for Charles River, and Bernstein for Delta Air.

Morgan Stanley Downgrades IQVIA Holdings to Equal-Weight, Lowers Price Target to $200

2026-06-17
Morgan Stanley analyst Kallum Titchmarsh downgrades IQVIA Holdings (NYSE:IQV) from Overweight to Equal-Weight and lowers the price target from $225 to $200.

Global Healthcare Infrastructure Strengthens IQV Amid Weak Liquidity

2026-06-15
IQVIA Holdings gains from its vast healthcare data, AI-driven analytics & global IT infrastructure, supporting expansion and solid growth.

Wiley and IQVIA Release Cross-Sector Report on AI’s Promise and Pressure Points Across Healthcare Value Chain

2026-06-15
HOBOKEN, N.J., June 15, 2026--Wiley (NYSE: WLY) and IQVIA (NYSE: IQV) today released Scientific Discovery & AI: The Science-to-Patient Journey, a cross-sector intelligence report drawing on candid dialogue among more than 25 senior leaders from pharma R&D, academic medicine, health systems, AI and technology, publishing and learned societies.

2 S&P 500 Stocks Worth Investigating and 1 Facing Headwinds

2026-06-12
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

Caris Life Sciences: The Discount To Peers Looks Hard To Ignore

2026-06-12
Caris Life Sciences leverages strong 2026 growth, cash flow, and a genomic database at a discount valuation. Read my thesis on CAI stock here.